首页> 外文OA文献 >Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders
【2h】

Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders

机译:扩增难治性突变系统,一种高灵敏度和简单的聚合酶链反应测定法,用于检测慢性骨髓增生性疾病中的JAK2 V617F突变。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

An acquired mutation in Janus kinase 2 (JAK2), V617F, has recently been identified in human myeloproliferative disorders. Detection of the mutation is helpful in differential diagnosis, prognosis, and predication of therapeutic response. Because the mutation can be present in a small proportion of granulocytic populations in myeloproliferative disorder patients, a highly sensitive detection method is required. In this study, we systematically optimized the reaction conditions of a published amplification refractory mutation system-polymerase chain reaction research protocol to make it a robust clinical diagnostic test. The modifications led to a clear demonstration of the V617F mutation in a patient who would have been easily missed by the original amplification refractory mutation system-polymerase chain reaction assay. The test detects the V617F mutation not only with a high analytic sensitivity of 0.05 to 0.1% but also with a high diagnostic specificity of 99%. In addition, the assay has the ability to distinguish cases with only mutant alleles from cases with mixed normal and mutant alleles. The assay is fast and easy to perform, and no special equipment other than thermocyclers is required. All these features make the assay readily and broadly applicable in clinical molecular diagnostic laboratories.
机译:最近在人类骨髓增生性疾病中发现了Janus激酶2(JAK2)V617F的一种获得性突变。突变的检测有助于鉴别诊断,预后和预测治疗反应。因为该突变可以存在于骨髓增生性疾病患者的一小部分粒细胞群中,所以需要一种高度灵敏的检测方法。在这项研究中,我们系统地优化了已发表的扩增难治性突变系统-聚合酶链反应研究方案的反应条件,使其成为可靠的临床诊断测试。这些修饰导致了患者中V617F突变的清晰显示,而原始扩增难治性突变系统-聚合酶链反应分析很容易错过该患者。该测试不仅可以检测V617F突变,而且分析灵敏度高达0.05至0.1%,诊断特异性也高达99%。另外,该测定法能够区分仅具有突变等位基因的病例与具有正常和突变等位基因混合的病例。该测定快速且容易进行,并且不需要除热循环仪以外的特殊设备。所有这些特征使得该测定容易且广泛地应用于临床分子诊断实验室。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号